Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway

Chang,Guanglei; Liu,Jian; Qin,Shu; Jiang,Youqin; Zhang,Peng; Yu,Hui; Lu,Kai; Zhang,Nan; Cao,Li; Wang,Ying; Li,Yong; Zhang,Dongying

doi:10.3892/ijmm.2017.3318

Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway

Authors:
- Guanglei Chang
- Jian Liu
- Shu Qin
- Youqin Jiang
- Peng Zhang
- Hui Yu
- Kai Lu
- Nan Zhang
- Li Cao
- Ying Wang
- Yong Li
- Dongying Zhang
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Sichuan 400016, P.R. China, Center for Perinatal Biology, Division of Pharmacology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
Published online on: December 12, 2017 https://doi.org/10.3892/ijmm.2017.3318
Pages: 1693-1703

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) and its analogues exert cardioprotective effects via modulating cardiomyocyte metabolism. Mitochondria play a pivotal role in the regulation of cell metabolism. It was hypothesized that treatment with exenatide, a GLP-1 analogue, may exert cardioprotective effects by improving mitochondrial function in an in vitro model of hypoxia/reoxygenation (H/R). H9c2 cells were employed to establish an in vitro model of H/R. Exenatide was added to the cells for 30 min prior to exposure to hypoxia. The GLP-1 receptor antagonist exendin‑(9‑39), the cyclic adenosine monophosphate (cAMP) inhibitor Rp-cAMPS and the protein kinase A (PKA) inhibitor H-89 were added to the cells for 10 min prior to treatment with exenatide. The release of lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) and cardiomyocyte apoptosis were evaluated. The characteristics of mitochondrial morphology and functions, including ATP synthesis, membrane potential (ΔΨm), mitochondrial permeability transition pore (mPTP), mitochondrial ATPase activity and oxidative stress, were determined. the mitochondrial uncoupling protein-3 (UCP-3) and nuclear respiratory factor-1 (Nrf-1) were also investigated by western blot analysis. Exenatide pretreatment significantly decreased LDH and CK-MB release and cardiomyocyte apoptosis in H9c2 cells subjected to H/R. More importantly, to the best of our knowledge, this is the first report of exenatide pretreatment decreasing mitochondrial abnormalities and reducing oxidative stress, while enhancing ATP synthesis, mitochondrial ATPase activity and ΔΨm in H9c2 cells subjected to H/R. Exenatide pretreatment also decreased mitochondrial calcium overload and inhibited the opening of mPTP in H9c2 cells subjected to H/R. Furthermore, exenatide pretreatment upregulated UCP-3 and Nrf-1 expression in H9c2 cells subjected to H/R. However, the abovementioned observed effects of exenatide were all abolished when exenatide was co-administered with exendin‑(9‑39), Rp-cAMPS and̸or H-89. Therefore, the GLP-1 analogue exenatide was found to exert cardioprotective effects in an in vitro model of H/R, and this cardioprotection may be attributed to the improvement of mitochondrial function. These effects are most likely associated with the activation of the GLP-1 receptor/cAMP/PKA signaling pathway.

View Figures

View References

1	Braunwald E and Kloner RA: Myocardial reperfusion: A double-edged sword? J Clin Invest. 76:1713–1719. 1985. View Article : Google Scholar : PubMed/NCBI
2	Acar E, Ural D, Bildirici U, Sahin T and Yılmaz I: Diabetic cardiomyopathy. Anadolu Kardiyol Derg. 11:732–737. 2011.PubMed/NCBI
3	Ong SB and Gustafsson AB: New roles for mitochondria in cell death in the reperfused myocardium. Cardiovasc Res. 94:190–196. 2012. View Article : Google Scholar :
4	Honda HM, Korge P and Weiss JN: Mitochondria and ischemia/reperfusion injury. Ann NY Acad Sci. 1047:248–258. 2005. View Article : Google Scholar : PubMed/NCBI
5	Lesnefsky EJ and Hoppel CL: Ischemia-reperfusion injury in the aged heart: Role of mitochondria. Arch Biochem Biophys. 420:287–297. 2003. View Article : Google Scholar : PubMed/NCBI
6	Sun L, Zhao M, Yu XJ, Wang H, He X, Liu JK and Zang WJ: Cardioprotection by acetylcholine: A novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway. J Cell Physiol. 228:1238–1248. 2013. View Article : Google Scholar
7	Yue R, Hu H, Yiu KH, Luo T, Zhou Z, Xu L, Zhang S, Li K and Yu Z: Lycopene protects against hypoxia/reoxygenation-induced apoptosis by preventing mitochondrial dysfunction in primary neonatal mouse cardiomyocytes. PLoS One. 7:e507782012. View Article : Google Scholar : PubMed/NCBI
8	Rehman H, Shi Y and Zhong Z: Ischemia/reperfusion inhibits mitochondrial biogenesis after partial hepatectomy in mice: 1738. Transplantation. 90:8392010. View Article : Google Scholar
9	Ren J, Pulakat L, Whaley-Connell A and Sowers JR: Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl). 88:993–1001. 2010. View Article : Google Scholar
10	Rimbaud S, Garnier A and Ventura-Clapier R: Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol Rep. 61:131–138. 2009. View Article : Google Scholar : PubMed/NCBI
11	Garber AJ: Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs. 21:45–57. 2012. View Article : Google Scholar
12	Mundil D, Cameron-Vendrig A and Husain M: GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 9:95–108. 2012. View Article : Google Scholar : PubMed/NCBI
13	Baggio LL and Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 132:2131–2157. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wei Y and Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358:219–224. 1995. View Article : Google Scholar : PubMed/NCBI
15	Chinda K, Chattipakorn S and Chattipakorn N: Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res. 9:256–269. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ravassa S, Zudaire A and Díez J: GLP-1 and cardioprotection: From bench to bedside. Cardiovasc Res. 94:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, et al: Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol. 12:1482013. View Article : Google Scholar : PubMed/NCBI
18	Zhao TC: Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: A new therapeutic approach for myocardial protection. Cardiovasc Diabetol. 12:902013. View Article : Google Scholar : PubMed/NCBI
19	Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A and Parkes DG: Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 9:762010. View Article : Google Scholar : PubMed/NCBI
20	Brown SB, Libonati JR, Selak MA, Shannon RP and Simmons RA: Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther. 24:197–205. 2010. View Article : Google Scholar : PubMed/NCBI
21	Tomas E, Stanojevic V and Habener JF: GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept. 167:177–184. 2011. View Article : Google Scholar : PubMed/NCBI
22	Park M, Youn B, Zheng XL, Wu D, Xu A and Sweeney G: Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced apoptosis. PLoS One. 6:e191432011. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Wang ZH, Shen CY, You ML, Xiao JF and Chen GQ: Differentiation of human bone marrow mesenchymal stem cells grown in terpolyesters of 3-hydroxyalkanoates scaffolds into nerve cells. Biomaterials. 31:1691–1698. 2010. View Article : Google Scholar
24	Kumar S, Kain V and Sitasawad SL: High glucose-induced Ca2þ overload and oxidative stress contribute to apoptosis of cardiac cells through mitochondrial dependent and independent pathways. Biochim Biophys Acta. 1820:907–920. 2012. View Article : Google Scholar : PubMed/NCBI
25	Odagiri K, Katoh H, Kawashima H, Tanaka T, Ohtani H, Saotome M, Urushida T, Satoh H and Hayashi H: Local control of mitochondrial membrane potential, permeability transition pore and reactive oxygen species by calcium and calmodulin in rat ventricular myocytes. J Mol Cell Cardiol. 46:989–997. 2009. View Article : Google Scholar : PubMed/NCBI
26	Tominaga H, Katoh H, Odagiri K, Takeuchi Y, Kawashima H, Saotome M, Urushida T, Satoh H and Hayashi H: Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 295:H105–H112. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM and Hausenloy DJ: Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 121:2012–2022. 2010. View Article : Google Scholar : PubMed/NCBI
28	Halestrap AP, Clarke SJ and Khaliulin I: The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta. 1767:1007–1031. 2007. View Article : Google Scholar : PubMed/NCBI
29	Li Q, Zhou LY, Gao GF, Jiao JQ and Li PF: Mitochondrial network in the heart. Protein Cell. 3:410–418. 2012. View Article : Google Scholar : PubMed/NCBI
30	Crow MT, Mani K, Nam YJ and Kitsis RN: The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res. 95:957–970. 2004. View Article : Google Scholar : PubMed/NCBI
31	Garlid KD, Costa AD, Quinlan CL, Pierre SV and Dos Santos P: Cardioprotective signaling to mitochondria. J Mol Cell Cardiol. 46:858–866. 2009. View Article : Google Scholar : PubMed/NCBI
32	Perrelli MG, Pagliaro P and Penna C: Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol. 3:186–200. 2011. View Article : Google Scholar : PubMed/NCBI
33	Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT and Shannon RP: Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 317:1106–1113. 2006. View Article : Google Scholar : PubMed/NCBI
34	Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT and Shannon RP: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 110:955–961. 2004. View Article : Google Scholar : PubMed/NCBI
35	Luque MA, González N, Márquez L, Acitores A, Redondo A, Morales M, Valverde I and Villanueva-Peñacarrillo ML: Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 173:465–473. 2002. View Article : Google Scholar : PubMed/NCBI
36	Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ and Jucker BM: Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency. PLoS One. 6:e235702011. View Article : Google Scholar : PubMed/NCBI
37	Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, et al: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 53:501–510. 2009. View Article : Google Scholar : PubMed/NCBI
38	Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ and Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI
39	Depre C, Ponchaut S, Deprez J, Maisin L and Hue L: Cyclic AMP suppresses the inhibition of glycolysis by alternative oxidizable substrates in the heart. J Clin Invest. 101:390–397. 1998. View Article : Google Scholar : PubMed/NCBI
40	De Rasmo D, Gattoni G, Papa F, Santeramo A, Pacelli C, Cocco T, Micelli L, Sardaro N, Larizza M, Scivetti M, et al: The β-adrenoceptor agonist isoproterenol promotes the activity of respiratory chain complex I and lowers cellular reactive oxygen species in fibroblasts and heart myoblasts. Eur J Pharmacol. 652:15–22. 2011. View Article : Google Scholar
41	Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR and Manfredi G: Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab. 9:265–276. 2009. View Article : Google Scholar : PubMed/NCBI
42	Valsecchi F, Ramos-Espiritu LS, Buck J, Levin LR and Manfredi G: cAMP and mitochondria. Physiology (Bethesda). 28:199–209. 2013.
43	Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, et al: Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 62:1697–1708. 2013. View Article : Google Scholar : PubMed/NCBI
44	Xiao YF, Nikolskaya A, Jaye DA and Sigg DC: Glucagon-like peptide-1 enhances cardiac L-type Ca²⁺ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol. 10:62011. View Article : Google Scholar
45	Bose AK, Mocanu MM, Carr RD and Yellon DM: Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 19:9–11. 2005. View Article : Google Scholar : PubMed/NCBI
46	Bose AK, Mocanu MM, Carr RD, Brand CL and Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 54:146–151. 2005. View Article : Google Scholar
47	Bose AK, Mocanu MM, Carr RD and Yellon DM: Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 21:253–256. 2007. View Article : Google Scholar : PubMed/NCBI
48	Krauss S, Zhang CY and Lowell BB: The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol. 6:248–261. 2005. View Article : Google Scholar : PubMed/NCBI
49	Teshima Y, Akao M, Jones SP and Marbán E: Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res. 93:192–200. 2003. View Article : Google Scholar : PubMed/NCBI
50	Bienengraeber M, Ozcan C and Terzic A: Stable transfection of UCP1 confers resistance to hypoxia/reoxygenation in a heart-derived cell line. J Mol Cell Cardiol. 35:861–865. 2003. View Article : Google Scholar : PubMed/NCBI
51	Scarpulla RC: Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem. 97:673–683. 2006. View Article : Google Scholar
52	Scarpulla RC: Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann NY Acad Sci. 1147:321–334. 2008. View Article : Google Scholar : PubMed/NCBI
53	Javadov S, Purdham DM, Zeidan A and Karmazyn M: NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling. Am J Physiol Heart Circ Physiol. 291:H1722–H1730. 2006. View Article : Google Scholar : PubMed/NCBI